JP2017536111A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536111A5 JP2017536111A5 JP2017522640A JP2017522640A JP2017536111A5 JP 2017536111 A5 JP2017536111 A5 JP 2017536111A5 JP 2017522640 A JP2017522640 A JP 2017522640A JP 2017522640 A JP2017522640 A JP 2017522640A JP 2017536111 A5 JP2017536111 A5 JP 2017536111A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- tim
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 134
- 102000036639 antigens Human genes 0.000 claims description 134
- 108091007433 antigens Proteins 0.000 claims description 134
- 239000012634 fragment Substances 0.000 claims description 129
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 48
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 47
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 47
- 229920001184 polypeptide Polymers 0.000 claims description 46
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 46
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 45
- 238000000338 in vitro Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 230000003915 cell function Effects 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000004064 dysfunction Effects 0.000 claims description 8
- 208000035473 Communicable disease Diseases 0.000 claims description 7
- 230000017274 T cell anergy Effects 0.000 claims description 7
- 231100000433 cytotoxic Toxicity 0.000 claims description 7
- 230000001472 cytotoxic effect Effects 0.000 claims description 7
- 230000001747 exhibiting effect Effects 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1419092.0 | 2014-10-27 | ||
| GB1419089.6 | 2014-10-27 | ||
| GB201419092A GB201419092D0 (en) | 2014-10-27 | 2014-10-27 | Anti-TIM-3 antibodies |
| GB201419089A GB201419089D0 (en) | 2014-10-27 | 2014-10-27 | Anti-TIM-3 antibodies |
| PCT/SG2015/050415 WO2016068803A1 (en) | 2014-10-27 | 2015-10-27 | Anti-tim-3 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536111A JP2017536111A (ja) | 2017-12-07 |
| JP2017536111A5 true JP2017536111A5 (enExample) | 2018-12-13 |
| JP6709215B2 JP6709215B2 (ja) | 2020-06-10 |
Family
ID=55857945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522640A Active JP6709215B2 (ja) | 2014-10-27 | 2015-10-27 | 抗ｔｉｍ−３抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10259874B2 (enExample) |
| EP (1) | EP3212231B1 (enExample) |
| JP (1) | JP6709215B2 (enExample) |
| KR (1) | KR20170075778A (enExample) |
| CN (2) | CN107405397B (enExample) |
| AU (1) | AU2015340056A1 (enExample) |
| CA (1) | CA2965960A1 (enExample) |
| SG (2) | SG11201703403TA (enExample) |
| WO (1) | WO2016068803A1 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015340056A1 (en) | 2014-10-27 | 2017-05-25 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| AU2016229189A1 (en) * | 2015-03-06 | 2017-09-21 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind TIM3 |
| EP3337826A1 (en) * | 2015-08-20 | 2018-06-27 | Sutro Biopharma, Inc. | Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies |
| KR102543118B1 (ko) | 2016-05-27 | 2023-06-14 | 아게누스 인코포레이티드 | 항-tim-3 항체 및 이의 사용 방법 |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US20190248893A1 (en) * | 2016-07-14 | 2019-08-15 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| JOP20190013A1 (ar) * | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| MX2019002242A (es) | 2016-08-26 | 2019-08-16 | Beigene Ltd | Anticuerpos anti-tim-3 y uso de los mismos. |
| WO2018075954A2 (en) | 2016-10-21 | 2018-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| US11312761B2 (en) | 2016-10-21 | 2022-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| JOP20190133A1 (ar) * | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1 |
| CN108264557B (zh) * | 2016-12-30 | 2021-08-24 | 惠和生物技术(上海)有限公司 | 一种结合cd3和t细胞负共刺激分子的双功能分子及其应用 |
| WO2018129090A1 (en) | 2017-01-03 | 2018-07-12 | Trellis Bioscience, Llc | Native human antibodies for immune checkpoint modulation targets tim-3 and b7-h3 |
| AU2018211985B2 (en) | 2017-01-26 | 2025-02-13 | Surrozen Operating, Inc. | Tissue-specific Wnt signal enhancing molecules and uses thereof |
| JP2021500916A (ja) | 2017-07-28 | 2021-01-14 | フェインズ セラピューティクス，インコーポレーテッド | 抗ｔｉｍ−３抗体及びその使用 |
| AU2018323462A1 (en) | 2017-08-28 | 2020-03-26 | Bristol-Myers Squibb Company | TIM-3 antagonists for the treatment and diagnosis of cancers |
| CN111954680B (zh) | 2017-11-10 | 2024-03-15 | 新加坡科技研究局 | IL2Rβ/共同γ链抗体 |
| JP7358361B2 (ja) * | 2018-01-12 | 2023-10-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｉｍ３に対する抗体およびその使用 |
| KR20200109339A (ko) | 2018-01-16 | 2020-09-22 | 브리스톨-마이어스 스큅 컴퍼니 | Tim3에 대한 항체를 사용하여 암을 치료하는 방법 |
| EP3758751A4 (en) * | 2018-02-28 | 2021-11-17 | Wuxi Biologics Ireland Limited. | MONOCLONAL ANTIBODIES AGAINST HUMAN LAG-3, METHOD OF MANUFACTURING AND USING THEREOF |
| CN110272489B (zh) * | 2018-03-15 | 2023-08-22 | 上海健信生物医药科技有限公司 | 一种针对tim-3的全人源化抗体分子, 抗原结合片段及其医药用途 |
| CN110305216B (zh) * | 2018-03-20 | 2022-09-02 | 无锡智康弘义生物科技有限公司 | 新型抗tim-3抗体 |
| JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用 |
| US11807683B2 (en) | 2018-04-12 | 2023-11-07 | Nanjing Leads Biolabs Co., Ltd. | Antibody binding TIM-3 and use thereof |
| US11884725B2 (en) | 2018-04-24 | 2024-01-30 | Ampsource Biopharma Shanghai Inc. | Antibody against TIM-3 and application thereof |
| WO2019241730A2 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| EA202190056A1 (ru) * | 2018-06-19 | 2021-05-28 | Ридженерон Фармасьютикалз, Инк. | АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ |
| JP2021530223A (ja) | 2018-07-09 | 2021-11-11 | スロゼン， インコーポレイテッド | 組織特異性Ｗｎｔシグナル増強分子及びその使用 |
| CA3117429A1 (en) * | 2018-11-01 | 2020-05-07 | Merck Patent Gmbh | Anti-tim-3 antibodies |
| JP7440509B2 (ja) | 2018-11-09 | 2024-02-28 | ベス イスラエル デアコネス メディカル センター | Ｃｄｃｐ１－標的化療法 |
| WO2020094836A1 (en) | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| WO2020094834A1 (en) | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| JP2022534982A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよびその使用 |
| CN110498855A (zh) * | 2019-07-25 | 2019-11-26 | 钟小泉 | 一种tim-3抗体及其用途 |
| CN110922478B (zh) * | 2019-12-07 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 针对特异表位的抗基孔肯雅热的全人源单克隆抗体及应用 |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| WO2021169948A1 (zh) * | 2020-02-24 | 2021-09-02 | 苏州恒康生命科学有限公司 | Tim3结合分子及其应用 |
| KR102572804B1 (ko) * | 2020-02-25 | 2023-08-31 | 국립암센터 | CD11b+ 세포에서 TIM-3의 발현 수준을 측정하는 암 진단 또는 예후 예측을 위한 정보제공 방법 |
| CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
| IL300916A (en) | 2020-08-31 | 2023-04-01 | Bristol Myers Squibb Co | Cell localization signature and immunotherapy |
| CN112094348B (zh) * | 2020-09-22 | 2021-11-30 | 首都医科大学附属北京胸科医院 | 抗人Tim3抗体或其功能性片段及其应用 |
| WO2022104280A1 (en) | 2020-11-16 | 2022-05-19 | Surrozen Operating, Inc. | Liver-specific wnt signal enhancing molecules and uses thereof |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| PT4267105T (pt) | 2020-12-28 | 2025-04-30 | Bristol Myers Squibb Co | Composições de anticorpos e métodos de utilização das mesmas |
| AU2021416156A1 (en) | 2020-12-28 | 2023-06-22 | Bristol-Myers Squibb Company | Methods of treating tumors |
| AU2022209703A1 (en) * | 2021-01-22 | 2023-08-17 | Elpis Biopharmaceuticals | Bispecific chimeric antigen receptors binding to cd19 and cd22 |
| EP4083065A1 (en) * | 2021-01-28 | 2022-11-02 | NantBio, Inc. | Anti-tim3 monoclonal antibodies and chimeric antigen receptors |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型ｃｄｃｐ１に対する抗体およびその使用 |
| US20240316104A1 (en) | 2021-06-29 | 2024-09-26 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| CN114181311B (zh) * | 2021-12-20 | 2023-06-20 | 华东师范大学 | 一种全人源抗DLL3 scFv及其在CART细胞治疗中的应用 |
| US20260035438A1 (en) * | 2022-03-04 | 2026-02-05 | The Scripps Research Institute | Human broadly neutralizing antibodies against betacoronaviruses |
| US20250206775A1 (en) | 2022-03-18 | 2025-06-26 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| AU2023281061A1 (en) | 2022-06-02 | 2024-12-05 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| US20260217828A1 (en) | 2023-01-31 | 2026-07-30 | University Of Rochester | Immune checkpoint blockade therapy for treating staphylococcus aureus infections |
| CN121712571A (zh) | 2023-08-15 | 2026-03-20 | 百时美施贵宝公司 | 陶瓷羟基磷灰石色谱流通法 |
| CN122459678A (zh) | 2023-12-29 | 2026-07-24 | 百时美施贵宝公司 | KRAS抑制剂与Treg耗竭剂的组合疗法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997000271A1 (en) | 1995-06-14 | 1997-01-03 | The Regents Of The University Of California | Novel high affinity human antibodies to tumor antigens |
| US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| ES2192426B1 (es) | 2000-05-11 | 2005-02-16 | Universidad De Vigo | Anticuerpo monoclonal humano sm50/20 que reconoce leucocitos humanos, y su uso en terapia. |
| JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
| CA2519528C (en) | 2003-03-19 | 2016-01-26 | Abgenix, Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
| JP2008500013A (ja) | 2003-10-03 | 2008-01-10 | ザ ブライハム アンド ウイメンズ ホスピタル，インコーポレイテッド | Ｔｉｍ−３ポリペプチド |
| CA2678008C (en) | 2005-06-17 | 2013-07-30 | Imclone Systems Incorporated | Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies |
| EP1957115B8 (en) | 2005-11-10 | 2014-03-05 | Celldex Therapeutics, Inc. | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
| WO2009097394A2 (en) * | 2008-01-29 | 2009-08-06 | The Brigham And Women's Hospital, Inc. | Methods for modulating a population of myeloid-derived suppressor cells and uses thereof |
| US9000131B2 (en) | 2008-07-31 | 2015-04-07 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
| US9221902B2 (en) | 2008-11-07 | 2015-12-29 | Fabrus, Inc. | Combinatorial antibody libraries and uses thereof |
| US8647623B2 (en) | 2009-04-10 | 2014-02-11 | Kyowa Hakko Kirin Co., Ltd | Method for treatment of blood tumor using anti-TIM-3 antibody |
| WO2011130417A2 (en) | 2010-04-15 | 2011-10-20 | Amgen Inc. | HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS |
| CN103079644B (zh) * | 2010-06-11 | 2017-02-15 | 协和发酵麒麟株式会社 | 抗tim‑3抗体 |
| US9163087B2 (en) * | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
| WO2013006490A2 (en) * | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| EP2543680A1 (en) * | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
| CN102392038B (zh) | 2011-11-01 | 2013-04-17 | 浙江大学 | 一种删除转基因水稻精米中的外源基因的表达载体及其应用 |
| CN102492038B (zh) * | 2011-12-09 | 2014-05-28 | 中国人民解放军军事医学科学院基础医学研究所 | 抗人Tim-3的中和性单克隆抗体L3D及其用途 |
| JP2015525781A (ja) | 2012-07-31 | 2015-09-07 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 免疫応答の調節 |
| AU2013302696B9 (en) * | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| CN103665164A (zh) * | 2012-10-24 | 2014-03-26 | 中国人民解放军军事医学科学院基础医学研究所 | 一种检测Tim-3的ELISA试剂盒 |
| WO2014070874A1 (en) | 2012-10-31 | 2014-05-08 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways |
| EP2948475A2 (en) * | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| JP2014162739A (ja) * | 2013-02-22 | 2014-09-08 | National Institute Of Biomedical Innovation | 二重特異性抗体及び医薬組成物 |
| AU2014374055B2 (en) | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| CN103936853B (zh) * | 2014-01-26 | 2016-08-17 | 中国人民解放军军事医学科学院基础医学研究所 | 一种检测tim-3试剂盒及其使用方法 |
| PL3099717T3 (pl) | 2014-01-31 | 2019-10-31 | Novartis Ag | Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| AU2015340056A1 (en) | 2014-10-27 | 2017-05-25 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
| CN104592388B (zh) | 2015-03-02 | 2017-05-31 | 中国人民解放军总医院 | 一种抗人Tim‑3的单克隆抗体的抗原结合部分 |
-
2015
- 2015-10-27 AU AU2015340056A patent/AU2015340056A1/en not_active Abandoned
- 2015-10-27 SG SG11201703403TA patent/SG11201703403TA/en unknown
- 2015-10-27 SG SG10201803042PA patent/SG10201803042PA/en unknown
- 2015-10-27 CA CA2965960A patent/CA2965960A1/en not_active Abandoned
- 2015-10-27 CN CN201580071169.9A patent/CN107405397B/zh active Active
- 2015-10-27 US US15/521,685 patent/US10259874B2/en active Active
- 2015-10-27 KR KR1020177014444A patent/KR20170075778A/ko not_active Withdrawn
- 2015-10-27 CN CN201910641759.0A patent/CN110294807B/zh active Active
- 2015-10-27 JP JP2017522640A patent/JP6709215B2/ja active Active
- 2015-10-27 WO PCT/SG2015/050415 patent/WO2016068803A1/en not_active Ceased
- 2015-10-27 EP EP15855010.3A patent/EP3212231B1/en active Active
-
2019
- 2019-03-06 US US16/294,474 patent/US11142574B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538441A5 (enExample) | ||
| JP2018500924A5 (enExample) | ||
| JP2018508475A5 (enExample) | ||
| AU2021200091B2 (en) | Chimeric antigen receptor compositions | |
| JP2018527912A5 (enExample) | ||
| JP2016529229A5 (enExample) | ||
| JP2019511222A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| US20200054736A1 (en) | Use of endogenous viral vaccine in chimeric antigen receptor t cell therapy | |
| RU2017116847A (ru) | Антитела к pd-1 | |
| EA201991099A1 (ru) | Антитела против cd73 и их применение | |
| JP2019535763A5 (enExample) | ||
| JP2018508215A5 (enExample) | ||
| JP2014518615A5 (enExample) | ||
| JP2017029157A5 (enExample) | ||
| JP2019509737A5 (enExample) | ||
| WO2016168773A2 (en) | Optimized pne-based chimeric receptor t cell switches and uses thereof | |
| JP2017522903A5 (enExample) | ||
| JP2018530331A5 (enExample) | ||
| RU2012156938A (ru) | Антитела против gdf8 человека | |
| JP2016505240A5 (enExample) | ||
| CN111511390B (zh) | 用于治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂 | |
| JP2016524592A5 (enExample) | ||
| JP2015529641A5 (enExample) | ||
| JP2017113019A5 (enExample) |